Role of C5a in inflammatory responses

Annual Review of Immunology

Volumn 23, Issue , 2005, Pages 821-852

  Guo, Ren Feng ^a   Ward, Peter A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

C5a receptor; C5L2; Complement; Inflammation

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR;

ACUTE LUNG INJURY; ASTHMA; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; EOSINOPHIL; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; ISCHEMIA; MONOCYTE; MULTIPLE ORGAN FAILURE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE; TISSUE INJURY;

ANIMALS; ASTHMA; BLOOD COAGULATION; COMPLEMENT ACTIVATION; COMPLEMENT C5A; HUMANS; HYPERSENSITIVITY; IMMUNITY, NATURAL; INFLAMMATION; LUNG; MODELS, IMMUNOLOGICAL; NEUTROPHILS; RECEPTOR, ANAPHYLATOXIN C5A; REPERFUSION INJURY; SEPSIS; SIGNAL TRANSDUCTION;

EID: 17644388462     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.23.021704.115835     Document Type: Review

References (156)

1. Ward PA. 2004. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4:133-42
2. Robbins RA, Russ WD, Rasmussen JK, Clayton MM. 1987. Activation of the complement system in the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 135:651-58
3. Linton SM, Morgan BP. 1999. Complement activation and inhibition in experimental models of arthritis. Mol. Immunol. 36:905-14
4. Welch TR. 2002. Complement in glomerulonephritis. Nat. Genet. 31:333-34
5. Ffrench-Constant C. 1994. Pathogenesis of multiple sclerosis. Lancet 343:271-75
6. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM. 2004. The role of the complement system in ischemia-reperfusion injury. Shock 21:401-9
7. Hawlisch H, Wills-Karp M, Karp CL, Kohl J. 2004. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol. Immunol. 41:123-31
8. Marder SR, Chenoweth DE, Goldstein IM, Perez HD. 1985. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg. J. Immunol. 134:3325-31
9. Goldstein IM, Weissmann G. 1974. Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J. Immunol. 113:1583-88
10. Sacks T, Moldow CF, Craddock PR, Bowers TK, Jacob HS. 1978. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J. Clin. Invest. 61:1161-67
11. Mollnes TE, Brekke OL, Fung M, Pure H, Christiansen D, et al. 2002. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100:1869-77
12. Schumacher WA, Fantone JC, Kunkel SE, Webb RC, Lucchesi BR. 1991. The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo. Agents Actions 34:345-49
13. Riedemann NC, Guo RF, Sarma VJ, Laudes IJ, Huber-Lang M, et al. 2002. Expression and function of the C5a receptor in rat alveolar epithelial cells. J. Immunol. 168:1919-25
14. Laudes IJ, Chu JC, Huber-Lang M, Guo RF, Riedemann NC, et al. 2002. Expression and function of C5a receptor in mouse microvascular endothelial cells. J. Immunol. 169:5962-70
15. Guo RF, Huber-Lang M, Wang X, Sarma V, Padgaonkar VA, et al. 2000. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J. Clin. Invest. 106:1271-80
16. Riedemann NC, Guo RF, Laudes IJ, Keller K, Sarma VJ, et al. 2002. C5a receptor and thymocyte apoptosis in sepsis. FASEB J. 16:887-88
17. Perianayagam MC, Balakrishnan VS, King AJ, Pereira BJ, Jaber BL. 2002. C5a delays apoptosis of human neutrophils by a phosphatidylinositol 3-kinase-signaling pathway. Kidney Int. 61:456-63
18. Guo RF, Riedemann NC, Laudes IJ, Sarma VJ, Kunkel RG, et al. 2002. Altered neutrophil trafficking during sepsis. J. Immunol. 169:307-14
19. Laudes IJ, Chu JC, Sikranth S, Huber-Lang M, Guo RF, et al. 2002. Anti-C5a ameliorates coagulation/fibrinolytic protein changes in a rat model of sepsis. Am. J. Pathol. 160:1867-75
20. Gerard NP, Hodges MK, Drazen JM, Weller PF, Gerard C. 1989. Characterization of a receptor for C5a anaphylatoxin on human eosinophils. J. Biol. Chem. 264:1760-66
21. Gerard NP, Gerard C. 1991. The chemotactic receptor for human C5a anaphylatoxin. Nature 349:614-17
22. Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, et al. 2003. C5L2, a nonsignaling C5a binding protein. Biochemistry 42:9406-15
23. Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, et al. 2000. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol. Immunol. 37:407-12
24. Chenoweth DE, Hugli TE. 1978. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes. Proc. Natl. Acad. Sci. USA 75:3943-47
25. Kurimoto Y, de Weck AL, Dahinden CA. 1989. Interleukin 3-dependent mediator release in basophils triggered by C5a. J. Exp. Med. 170:467-79
26. Werfel T, Oppermann M, Schulze M, Krieger G, Weber M, et al. 1992. Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 79:152-60
27. Haviland DL, McCoy RL, Whitehead WT, Akama H, Molmenti EP, et al. 1995. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J. Immunol. 154:1861-69
28. Schieferdecker HL, Schlaf G, Jungermann K, Gotze O. 2001. Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. Int. Immunopharmacol 1:469-81
29. Riedemann NC, Guo RF, Neff TA, Laudes IJ, Keller KA, et al. 2002. Increased C5a receptor expression in sepsis. J. Clin. Invest. 110:101-8
30. Huber-Lang M, Younkin EM, Sarma JV, Riedemann N, McGuire SR, et al. 2002. Generation of C5a by phagocytic cells. Am. J. Pathol 161:1849-59
31. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, et al. 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644-55
32. Bone RC, Sprung CL, Sibbald WJ. 1992. Definitions for sepsis and organ failure. Crit. Care Med. 20:724-26
33. Riedemann NC, Guo RF, Ward PA. 2003. The enigma of sepsis. J. Clin. Invest. 112:460-67
34. de Boer JP, Creasey AA, Chang A, Roem D, Eerenberg AJ, et al. 1993. Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect. Immun. 61:4293-301
35. Smedegard G, Cui LX, Hugli TE. 1989. Endotoxin-induced shock in the rat. A role for C5a. Am. J. Pathol. 135:489-97
36. Bengtson A, Heideman M. 1988. Anaphylatoxin formation in sepsis. Arch. Surg. 123:645-49
37. Nakae H, Endo S, Inada K, Takakuwa T, Kasai T, et al. 1994. Serum complement levels and severity of sepsis. Res. Commun. Chem. Pathol. Pharmacol. 84:189-95
38. Zhao L, Ohtaki Y, Yamaguchi K, Matsushita M, Fujita T, et al. 2002. LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood 100:3233-39
39. Sprong T, Brandtzaeg P, Fung M, Pharo AM, Hoiby EA, et al. 2003. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 102:3702-10
40. Hopken UE, Lu B, Geard NP, Gerard C. 1996. The C5a chemoattractant receptor mediates mucosal defense to infection. Nature 383:86-89
41. Huber-Lang MS, Younkin EM, Sarma JV, McGuire SR, Lu KT, et al. 2002. Complement-induced impairment of innate immunity during sepsis. J. Immunol. 169:3223-31
42. Ayala A, Herdon CD, Lehman DL, DeMaso CM, Ayala CA, Chaudry IH. 1995. The induction of accelerated thymic programmed cell death during polymicrobial sepsis: control by corticosteroids but not tumor necrosis factor. Shock 3:259-67
43. Ayala A, Chaudry IH. 1996. Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis. Shock 6:S27-38
44. Ayala A, Xu YX, Chung CS, Chaudry IH. 1999. Does Fas ligand or endotoxin contribute to thymic apoptosis during polymicrobial sepsis? Shock 11:211-17
45. Oberholzer C, Oberholzer A, Bahjat FR, Mintr RM, Tannahill CL, et al. 2001. Targeted adenovirus-induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proc. Natl Acad. Sci. USA 98:11503-8
46. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, et al. 2000. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 1:496-501
47. Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, et al. 2002. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 18:487-94
48. Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, et al. 1997. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch. Surg. 132:1263-70
49. Simon HU. 2003. Neutrophil apoptosis pathways and their modifications in inflammation. Immunol. Rev. 193:101-10
50. Meagher LC, Cousin JM, Seckl JR, Haslett C. 1996. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. 156:4422-28
51. Mohr M, Hopken U, Oppermann M, Mathes C, Goldmann K, et al. 1998. Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur. J. Clin. Invest. 28:227-34
52. Stevens JH, O'Hanley P, Shapiro JM, Mihm FG, Satoh PS, et al. 1986. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J. Clin. Invest. 77:1812-16
53. Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, et al. 1999. Protective effects of C5a blockade in sepsis. Nat. Med. 5:788-92
54. Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, et al. 2001. Role of C5a in multi-organ failure during sepsis. J. Immunol. 166:1193-99
55. Deitch EA. 1992. Multiple organ failure. Pathophysiology and potential future therapy. Am. Surg. 216:117-34
56. Baue AE, Durham R, Faist E. 1998. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): Are we winning the battle? Shock 10:79-89
57. Baue AE. 2000. Multiple organ failure-the discrepancy between our scientific knowledge and understanding and the management of our patients. Langenbecks Arch. Surg. 385:441-53
58. Baue AE. 2003. Sepsis, systemic inflammatory response syndrome, multiple organ dysfunction syndrome, and multiple organ failure: Are trauma surgeons lumpers or splitters? J. Trauma 55:997-98
59. Ebong SJ, Call DR, Bolgos G, Newcomb DE, Granger JI, et al. 1999. Immunopathologic responses to non-lethal sepsis. Shock 12:118-26
60. Faist E, Wichmann MW. 1997. Immunology in the severely injured. Chirurg 68:1066-70 (In German)
61. Nakae H, Endo S, Inada K, Yoshida M. 1996. Chronological changes in the complement system in sepsis. Surg. Today 26:225-29
62. Wang SD, Huang KJ, Lin YS, Lei HY. 1994. Sepsis-induced apoptosis of the thymocytes in mice. J. Immunol. 152:5014-21
63. Ayala A, Herdon CD, Lehman DL, Ayala CA, Chaudry IH. 1996. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood 87:4261-75
64. Barke RA, Roy S, Chapin RB, Charboneau R. 1994. The role of programmed cell death (apoptosis) in thymic involution following sepsis. Arch. Surg. 129:1256-62
65. Papathanassoglou ED, Moynihan JA, Ackerman MH. 2000. Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework. Crit. Care Med. 28:537-49
66. Stricter RM, Kasahara K, Allen RM, Standiford TJ, Rolfe MW, et al. 1992. Cytokine-induced neutrophil-derived interleukin-8. Am. J. Pathol 141:397-407
67. Hopken U, Mohr M, Struber A, Montz H, Burchardi H, et al. 1996. Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies. Eur. J. Immunol. 26:1103-9
68. Monsinjon T, Casque P, Chan P, Ischenko A, Brady JJ, et al. 2003. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 17:1003-14
69. Riedemann NC, Guo RF, Gao H, Sun L, Hoesel M, et al. 2004. Regulatory role of C5a on macrophage migration inhibitory factor release from neutrophils. J. Immunol. 173:1355-59
70. Wittmann M, Zwirner J, Larsson VA, Kirchhoff K, Begemann G, et al. 1999. C5a suppresses the production of IL-12 by IFN-γ-primed and lipopolysaccharide-challenged human monocytes. J. Immunol. 162:6763-69
71. Riedemann NC, Guo RF, Bernacki KD, Reuben JS, Laudes IJ, et al. 2003. Regulation by C5a of neutrophil activation during sepsis. Immunity 19:193-202
72. Pan ZK. 1998. Anaphylatoxins C5a and C3a induce nuclear factor κB activation in human peripheral blood monocytes. Biochim. Biophys. Acta 1443:90-98
73. Aird WC. 2003. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101:3765-77
74. Ikeda K, Nagasawa K, Horiuchi T, Tsuru T, Nishizaka H, et al. 1997. C5a induces tissue factor activity on endothelial cells. Thromb. Haemost. 77:394-98
75. Muhlfelder TW, Niemetz J, Kreutzer D, Beebe D, Ward PA, et al. 1979. C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J. Clin. Invest. 63:147-50
76. Carson SD, Johnson DR. 1990. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood 76:361-67
77. Horuk R. 1994. The interleukin-8-receptor family: from chemokines to malaria. Immunol. Today 15:169-74
78. Molad Y, Haines KA, Anderson DC, Buyon JP, Cronstein BN. 1994. Immunocomplexes stimulate different signalling events to chemoattractants in the neutrophil and regulate L-selectin and β2-integrin expression differently. Biochem. J. 299(Pt. 3):881-87
79. Jagels MA, Daffern PJ, Hugli TE. 2000. C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology 46:209-22
80. Guo RF, Riedemann NC, Bernacki KD, Sarma VJ, Laudes IJ, et al. 2003. Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB J. 13:1889-91
81. Seely AJ, Naud JF, Campisi G, Giannias B, Liu S, et al. 2002. Alteration of chemoattractant receptor expression regulates human neutrophil chemotaxis in vivo. Ann. Surg. 235:550-59
82. Van Epps DE, Simpson S, Bender JG, Chenoweth DE. 1990. Regulation of C5a and formyl peptide receptor expression on human polymorphonuclear leukocytes. J. Immunol. 144:1062-68
83. Naik N, Giannini E, Brouchon L, Boulay F. 1997. Internalization and recycling of the C5a anaphylatoxin receptor: evidence that the agonist-mediated internalization is modulated by phosphorylation of the C-terminal domain. J. Cell Sci. 110:2381-90
84. Gilbert TL, Bennett TA, Maestas DC, Cimino DF, Prossnitz ER. 2001. Internalization of the human N-formyl peptide and C5a chemoattractant receptors occurs via clathrin-independent mechanisms. Biochemistry 40:3467-75
85. Soruri A, Kiafard Z, Dettmer C, Riggert J, Kohl J, et al. 2003. IL-4 down-regulates anaphylatoxin receptors in monocytes and dendritic cells and impairs anaphylatoxin-induced migration in vivo. J. Immunol. 170:3306-14
86. Song GY, Chung CS, Chaudry IH, Ayala A. 2000. IL-4-induced activation of the Stat6 pathway contributes to the suppression of cell-mediated immunity and death in sepsis. Surgery 128:133-38
87. Tellado IM, McGowen GC, Christou NV. 1993. Decreased polymorphonuclear leukocyte exudation in critically ill anergic patients associated with increased adhesion receptor expression. Crit. Care Med. 21:1496-501
88. Meddows-Taylor S, Pendle S, Tiemessen CT. 2001. Altered expression of CD88 and associated impairment of complement 5a-induced neutrophil responses in human immunodeficiency virus type 1-infected patients with and without pulmonary tuberculosis. J. Infect. Dis. 183:662-65
89. Ishii Y, Kobayashi I, Kitamura S. 1989. Chemotactic factor generation and cell accumulation in acute lung injury induced by endotracheal acid instillation. Prostaglandins Leukot Essent. Fatty Acids 37:65-70
90. Winter SM, Paradis IL, Dauber JH, Griffith BP, Hardesty RL, et al. 1989. Proteins of the respiratory tract after heart-lung transplantation. Transplantation 48:974-80
91. Guo RF. Ward PA. 2002. Mediators and regulation of neutrophil accumulation in inflammatory responses in lung: insights from the IgG immune complex model. Free Radic. Biol. Med. 33:303-10
92. Czermak BJ, Lentsch AB, Bless NM, Schmal H, Friedl HP, ,et al. 1998. Role of complement in in vitro and in vivo lung inflammatory reactions. J. Leukoc. Biol. 64:40-48
93. Bozic CR, Lu B, Hopken UE, Gerard C, Gerard NP. 1996. Neurogenic amplification of immune complex inflammation. Science 273:1722-25
94. Mulligan MS, Schmid E, Beck-Schimmer B, Till GO, Friedl HP, et al. 1996. Requirement and role of C5a in acute lung inflammatory injury in rats. J. Clin. Invest. 98:503-12
95. Czermak BJ, Sarma V, Bless NM, Schmal H, Friedl HP, et al. 1999. In vitro and in vivo dependency of chemokine generation on C5a and TNF-α. J. Immunol. 162:2321-25
96. Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, et al. 1994. C5a-induced expression of P-selectin in endothelial cells. J. Clin. Invest. 94:1147-55
97. Mulligan MS, Schmid E, Till GO, Hugli TE, Friedl HP, et al. 1997. C5a-dependent up-regulation in vivo of lung vascular P-selectin. J. Immunol. 158:1857-61
98. Albrecht EA, Chinnaiyan AM, Varambally S, Kumar-Sinha C, Barrette TR, et al. 2004. C5a-induced gene expression in human umbilical vein endothelial cells. Am. J. Pathol. 164:849-59
99. Gao H, Guo RF, Speyer CL, Reuben J, Neff TA, et al. 2004. Stat3 activation in acute lung injury. J. Immunol. 172:7703-12
100. Garden DL, Granger DN. 2000. Pathophysiology of ischaemia-reperfusion injury. J. Pathol. 190:255-66
101. Milhoan KA, Lane TA, Bloor CM. 1992. Hypoxia induces endothelial cells to increase their adherence for neutrophils: role of PAF. Am. J. Physiol. Heart Circ. 263:H956-62
102. Goldman G, Welbourn R, Klausner JM, Valeri CR, Shepro D, et al. 1991. Thromboxane mediates diapedesis after ischemia by activation of neutrophil adhesion receptors interacting with basally expressed intercellular adhesion molecule-1. Circ. Res. 68:1013-19
103. Jerome SN, Dore M, Paulson JC, Smith CW, Korthuis RJ. 1994. P-selectin and ICAM-1-dependent adherence reactions: role in the genesis of postischemic no-reflow. Am. J. Physiol. Heart Circ. 266: H1316-21
104. Jaeschke H, Bautista AP, Spolarics Z, Spitzer JJ. 1991. Superoxide generation by Kupffer cells and priming of neutrophils during reperfusion after hepatic ischemia. Free Radic. Res. Commun. 15:277-84
105. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, et al. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146-51
106. x, an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x. Br. J. Pharmacol. 128:945-52
107. Stammberger U, Harnacher J, Hillinger S, Schmid RA. 2000. sCR1sLe ameliorates ischemia/reperfusion injury in experimental lung transplantation. J. Thorac. Cardiovasc. Surg. 120:1078-84
108. Lehmann TG, Koeppel TA, Kirschfink M, Gebhard MM, Herfarth C, et al. 1998. Complement inhibition by soluble complement receptor type 1 improves microcirculation after rat liver transplantation. Transplantation 66:717-22
109. Lehmann TG, Koeppel TA, Munch S, Heger M, Kirschfink M, et al. 2001. Impact of inhibition of complement by sCR1 on hepatic microcirculation after warm ischemia. Microvasc. Res. 62:284-92
110. Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechtman HB, et al. 1992. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat. J. Immunol. 149:1723-28
111. Huang J, Kim LJ, Mealey R, Marsh HC J Jr, Zhang Y, Tenner AJ, et al. 1999. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285:595-99
112. x- glycosylated complement inhibitory protein. Am. J. Physiol. Cell. Physiol. 281:C224-30
113. Bergamaschini L, Gobbo G, Gatti S, Caccamo L, Prato P, et al. 2001. Endothelial targeting with C!-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin. Exp. Immunol. 126:412-20
114. Horstick G, Berg O, Heimann A, Gotze O, Loos M, et al. 2001. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 104:3125-31
115. De Simoni MG, Storini C, Barba M, Catapano L, Arabia AM, et al. 2003. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J. Cereb. Blood Flow Metab. 23:232-39
116. Jordan JE, Montalto MC, Stahl GL. 2001. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 104:1413-18
117. Stahl GL, Xu Y, Hao L, Miller M, Buras JA, et al. 2003. Role for the alternative complement pathway in ischemia/reperfusion injury. Am. J. Pathol. 162:449-55
118. Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, et al. 2000. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J. Clin. Invest. 105:1363-71
119. Weiser MR, Williams JP, Moore FD J Jr, Kobzik L, Ma M, et al. 1996. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J. Exp. Med. 183:2343-48
120. Williams JP, Pechet TT, Weiser MR, Reid R, Kobzik L, et al. 1999. Intestinal reperfusion injury is mediated by IgM and complement. J. Appl. Physiol. 86:938-42
121. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, et al. 1998. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 97:2259-67
122. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, et al. 2003. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 108:1176-83
123. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, et al. 2003. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 108:1184-90
124. Tofukuji M, Stahl GL, Agah A, Metais C, Simons M, et al. 1998. Anti-C5a mono-clonal antibody reduces cardiopulmonary bypass and cardioplegia-induced coronary endothelial dysfunction. J. Thorac. Cardiovasc. Surg. 116:1060-68
125. de Vries B, Kohl J, Leclercq WK, Wolfs TG, van Bijnen AA, et al. 2003. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J. Immunol. 170:3883-89
126. Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, et al. 2003. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int. 63:134-42
127. Arumugam TV, Shiels IA, Woodruff TM, Reid RC, Fairlie DP, et al. 2002. Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J. Surg. Res. 103:260-67
128. Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, et al. 2004. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br. J. Pharmacol. 142:756-64
129. Arumugam TV, Woodruff TM, Stocks SZ, Proctor LM, Pollitt S, et al. 2004. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J. Hepatol. 40:934-41
130. Bless NM, Warner RL, Padgaonkar VA, Lentsch AB, Czermak BJ, et al. 1999. Roles for C-X-C chemokines and C5a in lung injury after hindlimb ischemia-reperfusion. Am. J. Physiol. 276:L57-63
131. Woodruff TM, Arumugam TV, Shiels IA, Reid RC, Fairlie DP, et al. 2004. Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. J. Surg. Res. 116:81-90
132. Horstick G, Heimann A, Gotze O, Hafner G, Berg O, et al. 1997. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 95:701-8
133. Buerke M, Prufer D, Dahm M, Oelert H, Meyer J, et al. 1998. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J. Pharmacol. Exp. Ther. 286:429-38
134. Buerke M, Murohara T, Lefer AM. 1995. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91:393-402
135. Bauernschmitt R, Bohrer H, Hagl S. 1998. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med. 24:635-38
136. Fitch JC, Rollins S, Matis L, Alford B, Aranki S, et al. 1999. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 100:2499-506
137. Cohn L, Elias JA, Chupp GL. 2004. Asthma: mechanisms of disease persistence and progression. Annu. Rev. Immunol. 22:789-815
138. Teran LM, Campos MG, Begishvilli BT, Schroder JM, Djukanovic R, et al. 1997. Identification of neutrophil chemotactic factors in bronchoalveolar lavage fluid of asthmatic patients. Clin. Exp. Allergy 27:396-105
139. Krug N, Tschernig T, Erpenbeck VJ, Hohlfeld JM, Kohl J. 2001. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am. J. Respir. Crit. Care Med. 164:1841-43
140. Andersson M, Michel L, Llull JB, Pipkorn U. 1994. Complement activation on the nasal mucosal surface-a feature of the immediate allergic reaction in the nose. Allergy 49:242-15
141. Kikuchi Y, Kaplan AP. 2002. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J. Allergy Clin. Immunol. 109:114-18
142. Maruo K, Akaike T, Ono T, Okamoto T, Maeda H. 1997. Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease. J. Allergy Clin. Immunol. 100:253-60
143. Abe M, Shibata K, Akatsu H, Shimizu N, Sakata N, et al. 2001. Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats. J. Immunol. 167:4651-60
144. Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, et al. 2001. Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J. Immunol. 166:2025-32
145. Taube C, Rha YH, Takeda K, Park JW, Joetham A, et al. 2003. Inhibition of complement activation decreases airway inflammation and hyperresponsiveness. Am. J. Respir. Crit. Care Med. 168:1333-41
146. Karp CL, Grupe A, Schadt E, Ewart SL, Keane-Moore M, et al. 2000. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat. Immunol. 1:221-26
147. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, et al. 1995. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J. Exp. Med. 182:1527-36
148. Soruri A, Riggert J, Schlott T, Kiafard Z, Dettmer C, Zwirner J. 2003. Anaphylatoxin C5a induces monocyte recruitment and differentiation into dendritic cells by TNF-α and prostaglandin E2-dependent mechanisms. J. Immunol. 171:2631-36
149. el-Lati SG, Dahinden CA, Church MK. 1994. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J. Invest. Dermatol. 102:803-6
150. Askenase PW, Tsuji RF. 2000. B-1 B cell IgM antibody initiates T cell elicitation of contact sensitivity. Curr. Top. Microbiol. Immunol. 252:171-77
151. Atkinson JJ, Senior RM. 2003. Matrix metalloproteinase-9 in lung remodeling. Am. J. Respir. Cell Mol. Biol. 28:12-24
152. Takafuji S, Ishida A, Miyakuni Y, Nakagawa T. 2003. Matrix metalloproteinase-9 release from human leukocytes. J. Investig. Allergol. Clin. Immunol. 13:50-55
153. Stimler NP, Bach MK, Bloor CM, Hugli TE. 1982. Release of leukotrienes from guinea pig lung stimulated by C5a des Arg anaphylatoxin. J. Immunol. 128:2247-52
154. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, et al. 1995. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377:68-71
155. Sabroe I, Pease JE, Williams TJ. 2000. Asthma and MIF: innately Th1 and Th2. Clin. Exp. Allergy 30:1194-96
156. Rossi AG, Haslett C, Hirani N, Greening AP, Rahman I, et al. 1998. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J. Clin. Invest. 101:2869-74